First Asia-Pacific hospital treats patients with RayStation and Radixact

News provided by

Oct 28, 2019, 07:30 ET

SUNNYVALE, Calif., Oct. 28, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) – Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning system RayStation® with Accuray's Radixact® Treatment Delivery System.

Lopburi has a focus on innovation and has been designated a national center of excellence for cancer treatment. Today it provides specialist treatment to patients in twelve provinces around the country. The hospital selected RayStation as its treatment planning system in 2015, largely due to the system's automated breast planning capabilities and unique multi-criteria optimization. Since its implementation, RayStation has enhanced the clinic's workflows, reduced calculation times and ensured consistently high-quality treatment plans.

The Lopburi team, led by Dr. Kriengkri Namthaisong, hospital director and Mr. Somsak Khaunchana, head of medical physics, recently installed the Radixact System, an innovative radiation therapy device that combines integrated CT imaging with a unique helical delivery platform enabling the delivery of radiation from 360 degrees around the patient. It can target a wide range of tumors, including those in the abdomen, brain, breast, lung and head & neck. Treatment accuracy and precision are achieved through daily 3D image guidance that helps ensure proper patient positioning and accurate dose delivery to the target even when anatomical changes occur.

Sutthisak Kulpisitthicharoen, M.D., radiation oncologist at Lopburi Cancer Hospital, says: "RayStation is easy to use and enables highly accurate treatment planning. We appreciate the multi-criteria optimization functionality, which is fast and gives the planner many possibilities. Contouring is precise and convenient, and the fallback planning feature means we can transfer treatment to an alternative machine if needed, without the need to re-plan. RayStation and Radixact are highly innovative systems, and the combination is excellent, particularly for complex cases."

Chonthon Phihuasuth, medical physicist at Lopburi Cancer Hospital, says: "Using RayStation and Radixact together improves treatment accuracy. The synergies between these innovations will reduce time both in treatment planning and treatment delivery, as well as increase efficiency. Radixact planning in RayStation enables us to achieve highly conformal dose distributions with lower doses to organs at risk, resulting in effective treatment with fewer complications for patients."

Johan Löf, founder and CEO of RaySearch, says: "Lopburi Cancer Hospital is a forward-looking center with a commitment to improve care through the latest technology. We are very pleased to support their planning needs for Accuray's advanced Radixact System. The synergies between the two systems bring great benefits for patients, as well as improving workflow efficiency for the clinic."

Joshua H. Levine, president and CEO at Accuray, says: "The Lopburi Cancer Hospital is raising the bar for other centers providing radiation therapy treatments. The clinical team's decision to treat cancer patients using the combination of RayStation and Radixact will expand access to state-of-the-art cancer treatment technologies for the people of Thailand. Together, RayStation and Radixact provide capabilities that align well with the hospital's goal of delivering the most effective treatments possible."

About Lopburi Cancer Hospital
Lopburi Cancer Hospital is a leading facility in the Mueang district of Thailand and has been designated a national center of excellence. The center is a pioneer of advanced technology and treats patients from provinces around the country using techniques such as TomoTherapy® as well as conventional radiation therapy.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Accuray Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, experiences and results, patient experiences and outcomes, and the expansion of access to cancer treatment technologies in Thailand. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of Accuray's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified under the heading "Risk Factors" in the Accuray 's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 23, 2019, and as updated periodically with Accuray 's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or Accuray management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare®*, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide. More information about RaySearch is available at www.raysearchlabs.com

* Subject to regulatory clearance in some markets.

For further information, please contact:
RaySearch:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
[email protected]

Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
[email protected]

Accuray:
Beth Kaplan, Public Relations Director, Accuray
Telephone: +1 (408) 789-4426
[email protected]

Jayme Maniatis, MSLGROUP
Telephone: +1 (781) 684-6610
[email protected]

SOURCE Accuray Incorporated